Viramontes-Madrid José Luis, Jerjes-Sánchez Carlos, Pelaez-Ballestas Ingris, Aguilar-Chiu Artemisa, Hernández-Garduño Adolfo G
Servicio de Urgencias, Hospital de Enfermedades Cardiovasculares y del Tórax, Centro Médico del Norte, Instituto Mexicano del Seguro Social, Monterrey, NL.
Rev Invest Clin. 2002 May-Jun;54(3):192-7.
To determine the frequency of concurrent use of cisapride, astemizole and terfenadine with macrolides and azole antimitotics, drug combinations that have been reported in the literature as producing a pharmacological interaction associated with potentially fatal ventricular arrhythmias.
A retrospective analysis of a total of 72,444 prescriptions generated by 611 physicians during a 6 months period for ambulatory patients, was performed. The database included a register of automatic alerts produced every time a predetermined drug combination was detected.
145 potentially risk situations were detected, with an incidence rate to 2.1 cases per 1,000 prescriptions, which increases to 6.2% when prescriptions for terfenadine, astemizole, and cisapride were included, with 12, 9 y 5%, respectively. Only 36 physicians (6%) wrote prescriptions producing alerts, and about half (45%) were pediatricians. The same physician prescribed both drugs in 31% of the cases.
The use of drug combinations associated with a high risk of potentially fatal ventricular arrhythmias is relatively high in Mexico. An electronic online detecting system showed to be useful in preventing this kind of potential pharmacological interactions.
确定西沙必利、阿司咪唑和特非那定与大环内酯类及唑类抗真菌药同时使用的频率,文献报道这些药物组合会产生与潜在致命性室性心律失常相关的药理相互作用。
对611名医生在6个月期间为门诊患者开具的总共72444份处方进行回顾性分析。该数据库包括每次检测到预定药物组合时生成的自动警报记录。
检测到145种潜在风险情况,发病率为每1000份处方2.1例,若将特非那定、阿司咪唑和西沙必利的处方包括在内,发病率则升至6.2%,其中特非那定、阿司咪唑和西沙必利的发病率分别为12%、9%和5%。只有36名医生(6%)开具了产生警报的处方,约一半(45%)是儿科医生。在31%的病例中,同一名医生开具了这两种药物。
在墨西哥,与潜在致命性室性心律失常高风险相关的药物组合使用相对频繁。电子在线检测系统在预防这类潜在药理相互作用方面显示出有用性。